Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Subscribe To Our Newsletter & Stay Updated
